Show simple item record

dc.contributor.authorNdzibongwana, Sethu
dc.contributor.authorNgobese, Samukelo
dc.contributor.authorSayed, Ahmad
dc.contributor.authorShongwe, Ciniso
dc.contributor.authorWhite-Phillips, Simon
dc.contributor.authorJoubert, Jacques
dc.date.accessioned2022-10-27T10:34:51Z
dc.date.available2022-10-27T10:34:51Z
dc.date.issued2019
dc.identifier.citationNdzibongwana, S.; Ngobese, S.; Sayed, A.; Shongwe, C.; White-Phillips, S.; Joubert, J. Structural Analysis, Molecular Modelling and Preliminary Competition Binding Studies of AM-DAN as a NMDA Receptor PCP-Site Fluorescent Ligand. Molecules 2019, 24, 4092. https://doi.org/10.3390/molecules24224092en_US
dc.identifier.issn1420-3049
dc.identifier.urihttps://doi.org/10.3390/molecules24224092
dc.identifier.urihttp://hdl.handle.net/10566/8081
dc.description.abstractExcitotoxicity related to the dysfunction of the N-methyl-d-aspartate receptor (NMDAR) has been indicated to play an integral role in the pathophysiology of multiple disease states, including neurodegenerative disorders such as Parkinson’s disease. There is a notable gap in the market for novel NMDAR antagonists, however current methods to analyse potential antagonists rely on indirect measurements of calcium flux and hazardous radioligand binding assays. Recently, a fluorescent NMDAR ligand, N-adamantan-1-yl-dimethylamino-1-naphthalenesulfonic acid, known as AM-DAN was developed by our group. Additional studies on this ligand is necessary to evaluate its potential as a biological tool in NMDAR research. Therefore, this study was aimed at conducting structural analyses, fluorescence experiments, high-accuracy NMDAR molecular modelling and NMDAR phencyclidine (PCP) site competition binding studies using AM-DAN. Results revealed that AM-DAN has appropriate structural properties, significant fluorescent ability in various solvents and is able to bind selectively and compete for the PCP-binding site of the NMDAR. Therefore, AM-DAN holds promise as a novel fluorescent ligand to measure the affinity of prospective drugs binding at the NMDAR PCP-site and may circumvent the use of radioligands.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.subjectMolecular modellingen_US
dc.subjectFluorescent liganden_US
dc.subjectPharmacyen_US
dc.subjectFluorescent bioassayen_US
dc.subjectAmantadineen_US
dc.titleStructural analysis, molecular modelling and preliminary competition bnding studies of AM-DAN as a NMDA Receptor PCP-Site Fluorescent Liganden_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record